Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Shin, Junghoon; Chung, Jin Haeng; Kim, Se Hyun; Lee, Kyu Sang; Suh, Koung Jin; Lee, Ji Yun; Kim, Ji Won; Lee, Jeong-Ok; Kim, Jin Won; Kim, Yu Jung; Lee, Moon Hyoung; Kim, Jee Hyun; Bang, Soo Mee; Lee, Jong Seok

doi:10.4143/crt.2018.537

Cited by 65 publications

(62 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A higher proportion of chemotherapy-treated patients in our study (48%) had a change in PD-L1 TPS, compared to other studies, showing changes in 3-41% of the patients [15][16][17][18][19][20]. The findings support the theory of possible chemotherapy-induced changes in the immune microenvironment and increment of tumor antigenicity, leading to changes in PD-L1 TPS [22].…”

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothsupporting

confidence: 76%

“…The field of research in PD-L1 TPS changes in NSCLC is mainly dominated by retrospective studies including patients with localized/ resectable disease, having received neo-adjuvant or adjuvant chemotherapy [15][16][17][18][19][20][21]. To our knowledge, results from prospective studies are in general limited [14] and we have not been able to identify studies looking specifically at PD-L1 TPS changes.…”

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothmentioning

confidence: 99%

“…To our knowledge, results from prospective studies are in general limited [14] and we have not been able to identify studies looking specifically at PD-L1 TPS changes. The retrospective studies have demonstrated a trend towards an up-regulation of PD-L1 TPS after chemotherapy/at time of recurrence [15][16][17][18][19][20][21].…”

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothmentioning

confidence: 99%

See 2 more Smart Citations

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

et al. 2020

View full text Add to dashboard Cite

Re-biopsy in progressive advanced Non-Small-Cell Lung Cancer (NSCLC) after first line treatment may reveal information about evolving tumor biology during treatment. Our study aims to investigate the feasibility, risk of complications, and clinical relevance of performing re-biopsy systematically. Materials and methods: NSCLC patients with advanced, non-targetable disease, receiving first line systemic treatment, were included in a prospective single-centre study (NCT03512847). A diagnostic biopsy was performed at baseline and repeated at time of progression, preferentially from the progressive lesions as determined by CT or PET/CT. The primary endpoint was feasibility, including complication rate to re-biopsy. Secondary endpoints were clinical relevance, defined as a potential of changing treatment or follow-up, due to new histological evidence, specifically a change in PD-L1 Tumor Proportion Score (TPS). Results: Fifty-one patients with progressive advanced NSCLC had re-biopsy performed. Median time from patients' acceptance to biopsy was seven days (range: 0-31). Complication rate was 6% (n = 3) represented by pneumothorax, hydro-pneumothorax and pneumonia, respectively. No severe or chronic complications occurred. Sufficient material for PD-L1 analyses was obtained in 46 of 51 patients: the remaining five cases had insufficient tissue for analyses, no malignant cells/only suspected malignant cells, questioning whether progression was real. PD-L1 TPS change was observed in 33% of patients (n = 15) and 17% (n = 8) had potentially clinically relevant changes. A significantly higher chance of PD-L1 TPS change was observed in chemotherapy-treated patients. Conclusion: Our study showed that re-biopsy is feasible, with low risk of complications, and can be clinically relevant in patients with suspected progression in advanced NSCLC.

show abstract

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothsupporting

confidence: 76%

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothmentioning

confidence: 99%

Section: Changes In Pd-l1 From Baseline To Progression 621 Chemothmentioning

confidence: 99%

See 1 more Smart Citation

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A study conducted by Peng et al [55] supported this hypothesis by showing that, in ovarian cancer, paclitaxel can induce tumor cells to overexpress PD-L1 through the NF-κB pathway, thereby promoting the formation of a tumor immunosuppressive microenvironment. Shin et al [56] demonstrated that platinum-based chemotherapy can improve the expression level of PD-L1 in tumor cells of NSCLC patients. Thus, in this situation, blocking PD-L1 may achieve significant therapeutic effect, which explained why sequential therapy was still effective, while the addition of ipilimumab turned out to be invalid.…”

Section: Discussionmentioning

confidence: 99%

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

et al. 2020

World J Surg Onc

View full text Add to dashboard Cite

Background: Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy, have been applied in the treatment of multiple malignancies. Real-world data have suggested that smoking status may be associated with the efficacy of anti-PD-1/PD-L1 therapy. Hereby, to evaluate "smoking benefit or not", we included numerous high-quality randomized controlled clinical trials (RCTs) without any restriction on category. Methods: A systematic search of online database was performed from July 2010 to July 2019. Eligible studies included phase II/III RCTs comparing PD-1/PD-L1 inhibitors with chemotherapy in the treatment of multiple carcinomas and contained subgroup analysis of smoking status. Then, related hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) were pooled.Results: In the initial meta-analysis, compared with chemotherapy, the OS of non-smokers (HR, 0.81; 95% CI, 0.67-0.98) and smokers (HR, 0.77; 95% CI, 0.71-0.83) were significantly prolonged with PD-1/PD-L1 inhibitors. Outcomes from subgroup analysis showed that in anti-PD-1/PD-L1 monotherapy groups, non-smokers showed no significant improvement in OS (HR, 0.94; 95% CI, 0.83-1.06), while the OS of smokers was significantly prolonged (HR, 0.79; 95% CI, 0.74-0.85); in groups of PD-1/PD-L1 inhibitors combined with chemotherapy, the OS of non-smokers (HR, 0.45; 95% CI, 0.28-0.71) and smokers (HR, 0.72; 95% CI, 0.61-0.85) were significantly prolonged. Combined ipilimumab and chemotherapy showed no significance in both groups. Conclusion:Smokers benefit from either anti-PD-1/PD-L1 monotherapy or the combined regimen compared with chemotherapy. Considering cost-effectiveness, monotherapy was recommended to smokers. For non-smokers, only the combined regimen was feasible in non-small cell lung cancer.

show abstract

“…The case described in this report adds to the increasingly being of change in PD-L1 expression during therapy with either chemotherapy, targeted or immunotherapy [11][12][13][14]. Neoadjuvant chemotherapy may up-regulate the expression of PD-L1 in lung squamous cell carcinoma as was recently published [15].…”

Section: Discussionmentioning

confidence: 53%

Altered PD-L1 Expression in Non-Small Cell Lung Cancer Patient After Induction Chemotherapy: A Case Report

Nasr¹,

Ghoche²,

Diab³

et al. 2019

J Med Cases

View full text Add to dashboard Cite

Targeting the immune checkpoint of programmed death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) with immunotherapy has improved the treatment of many tumors including non small cell lung cancer (NSCLC). Checking PD-L1 status must be done during the course of therapy. Changes of PD-L1 status with therapy have been described in several cancer subtypes with different treatment modalities including chemotherapy and immunotherapy. Here we present a case report of a locally advanced squamous lung carcinoma patient presenting a decrease of PD-L1 level after chemotherapy. This case will be added to the few reports describing such changes in PD-L1 expression after different treatment modalities. More data are needed to understand the underlying mechanisms and its treatment implications.

show abstract

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

Cited by 65 publications

References 31 publications

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Altered PD-L1 Expression in Non-Small Cell Lung Cancer Patient After Induction Chemotherapy: A Case Report

Contact Info

Product

Resources

About